Targeting Wnt/β-catenin signaling by microRNAs as a therapeutic approach in chemoresistant osteosarcoma

Biochem Pharmacol. 2021 Nov:193:114758. doi: 10.1016/j.bcp.2021.114758. Epub 2021 Sep 3.

Abstract

Osteosarcoma (OS) is an adolescent and young adult malignancy that mostly occurs in long bones. The treatment of OS is still a big challenge for clinicians due to increasing chemoresistance, and many efforts are being made today to find more beneficial treatments. In this regard, the use of microRNAs has shown a high capacity to develop promising therapies. By targeting cancer-involved signaling pathways, microRNAs reduce the cellular level of these protein pathways; thereby reducing the growth and invasion of tumors, and even leading cancer cells to apoptosis. One of these oncogenic pathways that play an important role in OS development and can be targeted by microRNAs is the Wnt/β-catenin signaling pathway. Hence, the first goal of this review article is to explain the cross-talk of microRNAs and the Wnt/β-catenin signaling in OS and then discussing recent findings of the use of microRNAs as a therapeutic approach in OS.

Keywords: Bone malignancy; Targeted therapy; miRNA.

Publication types

  • Review

MeSH terms

  • Bone Neoplasms / therapy*
  • Drug Resistance, Neoplasm*
  • Humans
  • MicroRNAs / therapeutic use*
  • Osteosarcoma / therapy*
  • Wnt Proteins / genetics
  • Wnt Proteins / metabolism*
  • beta Catenin / genetics
  • beta Catenin / metabolism*

Substances

  • CTNNB1 protein, human
  • MicroRNAs
  • Wnt Proteins
  • beta Catenin